Rachel E. Fenner

Rachel E. Fenner

Auto-generated profile, based on publicly available information

Rachel E. Fenner

Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom. 2

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SCSean R. Corcoran
Sean R. Corcoran
JPJames D. Phelan
James D. Phelan
JCJaewoo Choi
Jaewoo Choi
GSGalina Shevchenko
Galina Shevchenko
RFRachel E. Fenner
Rachel E. Fenner
LSLouis M. Staudt
Louis M. Staudt
Polatuzumab vedotin (Pola-V) is an antibody–drug conjugate directed to the CD79B subunit of the B-cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V improves outcomes in diffuse large B-cell lymphoma (DLBCL). To identify determinants of Pola-V sensitivity, we used CRISPR-Cas9 screening for genes that modulated Pola-V toxicity for lymphomas or the surface expression of its target, CD79B. Our results reveal the striking impact of CD79B glycosylation on Pola-V epitope availability on the lymphoma cell surface and on Pola-V toxicity. Genetic, pharmacological, and enzymatic approaches that remove sialic acid from N-linked glycans enhanced lymphoma killing by Pola-V. Pola-V toxicity was also modulated by KLHL6, an E3 ubiquitin ligase that is recurrently inactivated in germinal center derived lymphomas. We reveal how KLHL6 targets CD79B for degradation in normal and malignant germinal center B cells, thereby determining expression of the surface BCR complex. Our findings suggest precision medicine strategies to optimize Pola-V as a lymphoma therapeutic. Significance: These findings unravel the molecular basis of response heterogeneity to Pola-V and identify approaches that might be deployed therapeutically to enhance the efficacy of CD79B-specific tumor killing. In addition, they reveal a novel post-translational mechanism used by normal and malignant germinal center B cells to regulate expression of the BCR. See related commentary by Leveille, p. 1577 See related article by Meriranta et al.

4 September 2024
Verified
Other
Open access
PDF file
SCSean R. Corcoran
Sean R. Corcoran
JPJames D. Phelan
James D. Phelan
JCJaewoo Choi
Jaewoo Choi
GSGalina Shevchenko
Galina Shevchenko
RFRachel E. Fenner
Rachel E. Fenner
LSLouis M. Staudt
Louis M. Staudt
KLHL6 loss does not score as a negative regulator of surface CD79B or Pola-V sensitivity in CRISPR screens of ABC DLBCL cell lines and KLHL6 loss does not sensitize to MMAE


4 September 2024
Verified
Other
Open access
PDF file
SCSean R. Corcoran
Sean R. Corcoran
JPJames D. Phelan
James D. Phelan
JCJaewoo Choi
Jaewoo Choi
GSGalina Shevchenko
Galina Shevchenko
RFRachel E. Fenner
Rachel E. Fenner
LSLouis M. Staudt
Louis M. Staudt
CD79B is degraded in a lysosomal, not proteasomal manner

4 September 2024
Verified
Other
Open access
SCSean R. Corcoran
Sean R. Corcoran
JPJames D. Phelan
James D. Phelan
JCJaewoo Choi
Jaewoo Choi
GSGalina Shevchenko
Galina Shevchenko
RFRachel E. Fenner
Rachel E. Fenner
LSLouis M. Staudt
Louis M. Staudt
Knockout of the E3 ligase KLHL6 results in increased cell surface CD79B in a human model of GCB DLBCL

4 September 2024
Verified
Other
Open access
PDF file
SCSean R. Corcoran
Sean R. Corcoran
JPJames D. Phelan
James D. Phelan
JCJaewoo Choi
Jaewoo Choi
GSGalina Shevchenko
Galina Shevchenko
RFRachel E. Fenner
Rachel E. Fenner
LSLouis M. Staudt
Louis M. Staudt
Mutation of CD79A and CD79B glycosylated residues does not alter sensitivity to MMAE